Top 14 medical and healthcare startups in Shanghai
May 03, 2026
|
Like
15
1
Funding: $418.5M
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. The company’s pipeline is headed up by Ori-C101, a GPC3-targeted autologous CAR-T therapy against hepatocellular carcinoma (HCC). The biotech is now gearing up for further studies with the ultimate aim of making Ori-C101 the first globally-approved CAR-T for HCC.
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. The company’s pipeline is headed up by Ori-C101, a GPC3-targeted autologous CAR-T therapy against hepatocellular carcinoma (HCC). The biotech is now gearing up for further studies with the ultimate aim of making Ori-C101 the first globally-approved CAR-T for HCC.
2
Funding: $100M
OTR Therapeutics is a biotechnology company developing platform-based treatments using modular RNA and delivery systems. Its pipeline covers differentiated programs that target significant treatment gaps in immunology and inflammation, oncology and neurologу. The company is a member of Bayer’s Co.Lab life sciences incubator network.
OTR Therapeutics is a biotechnology company developing platform-based treatments using modular RNA and delivery systems. Its pipeline covers differentiated programs that target significant treatment gaps in immunology and inflammation, oncology and neurologу. The company is a member of Bayer’s Co.Lab life sciences incubator network.
3
Funding: $308M
Rapport Therapeutics develops drugs for the treatment of central nervous system disorders. Its lead asset RAP-219 is designed for the treatment of focal epileptic seizures and primary generalized tonic-clonic seizures. It's a potential first-in-class negative allosteric modulator of the AMPA receptor, specific for TARPγ8. RAP-219 has multiple indications, including focal epilepsy and acute mania in bipolar disorder, as well as an anticonvulsant. The company has secured development and commercialization rights for its lead drug in Greater China.
Rapport Therapeutics develops drugs for the treatment of central nervous system disorders. Its lead asset RAP-219 is designed for the treatment of focal epileptic seizures and primary generalized tonic-clonic seizures. It's a potential first-in-class negative allosteric modulator of the AMPA receptor, specific for TARPγ8. RAP-219 has multiple indications, including focal epilepsy and acute mania in bipolar disorder, as well as an anticonvulsant. The company has secured development and commercialization rights for its lead drug in Greater China.
4
Funding: $417.8M
Harbour BioMed is a global biopharmaceutical company developing innovative therapeutics in the field of immuno-oncology and inflammatory diseases.
Harbour BioMed is a global biopharmaceutical company developing innovative therapeutics in the field of immuno-oncology and inflammatory diseases.
5
Funding: $190M
JW is focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.
JW is focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.
8
Funding: $65.5M
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure.
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure.
10
Funding: $23.1M
Mobile social platform bringing better healthcare experience to its communities, especially insurance members and employees. Provides AI voice-based virtual health assistant for insurers and employers
Mobile social platform bringing better healthcare experience to its communities, especially insurance members and employees. Provides AI voice-based virtual health assistant for insurers and employers
11
Funding: $23.1M
The CareVoice is a health InsurTech company that provides a mobile-based data-driven SaaS platform.
The CareVoice is a health InsurTech company that provides a mobile-based data-driven SaaS platform.
12
Funding: $15M
Siyi Intelligence specializes in the design, development and commercialization of cutting-edge solutions in rehabilitation, in particular medical rehabilitation robots.
Siyi Intelligence specializes in the design, development and commercialization of cutting-edge solutions in rehabilitation, in particular medical rehabilitation robots.
14
Junshi Biosciences is an innovation-driven biopharmaceutical company which is dedicated to the discovery and development of innovative drugs and their clinical research and commercialization on a global scale.
★
See also:
